VivoSeq
Ophthalmology

Optic Atrophy

3

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Optic Atrophy is an early-stage landscape with 3 programs across 3 companies. The most active players are Roche, PYC Therapeutics, Metro International Biotech, LLC. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

1 program

Phase 1P

PYC Therapeutics

1 program

Phase 2M

Metro International Biotech, LLC

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

Epoetin Beta

Roche

Phase 21

PYC-001

PYC Therapeutics

Phase 31

Nicotinamide

Metro International Biotech, LLC

Approved
No programs

Analysis

Trial Status

3

clinical trials

Recruiting1 · 33%
Active, not recruiting1 · 33%
Completed1 · 33%

Clinical Trials

Trial Activity

Tolerance and Efficacy Nicotinamide (vitamin B3) in Dominant Optic Atrophy OPA1
Recruiting·UUniversity Hospital, Angers·Phase 2/3·NCT06007391·25 enrolled
SAD of IVT PYC-001 in OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy (Sundew)
Active, not recruiting·PPYC Therapeutics·Phase 1·NCT06461286·18 enrolled
Systemic Erythropoietin Injection in Patients Having Optic Atrophy
Completed·—·Phase 1/2·NCT04680143·10 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)